ZURA BIO LTD
ZURANASDAQπ #3027 by market capEarnings Nov 18US Equity
$3.85βΌ $0.51 (β11.61%)
After hours Β· at closeTrack ZURA
Get earnings, price moves & breaking news on Telegram
24hβΌ 11.6%
7dβ² 9.1%
14dβΌ 10.1%
30dβΌ 3.9%
ytdβΌ 26.5%
1yβ² 1.7%
π¦Market Cap
$368M
Small Cap
πRevenue Growth (YoY)
0.0%
Slowing
πGross Margin
0.0%
Thin
π΅FCF Margin
0.0%
Thin
βοΈP/S Ratio
0.0x
Cheap
Otter Score
β
Insufficient data
Trading Snapshot
- Day Range
- $3.80 β $4.49
- 52-Week Range
- $3.25 β $7.44
- Volume (shares)
- 297,013
- Avg Volume (shares)
- β
- Shares Outstanding
- 95.8M
- Next Earnings
- 2026-11-18
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -3.7
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-0.73
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +44.2%
ZURA BIO LTD
ZURAFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$75Mβ² +36.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$65Mβ² +130.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
94.2Mβ² +44.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$109MβΌ β$67M YoY
StockOtter Β· stockotter.spaceAbout ZURA BIO LTD
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7RΞ± inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst Ratings
βConsensus
Buy
14 analysts
Strong Buy7
Buy6
Hold1
Sell0
Strong Sell0
Ratings as of Oct 2026
Latest News & Updates
News unavailable.